Vania Phuoc, MD, MBA

Cancer Focus:
Benign Hematology, Breast Cancer, Ductal Carcinoma In Situ, Hodgkin Lymphoma, Multiple Myeloma-Plasma Cell Disorders, Non-Hodgkin Lymphoma

 

Dr. Vania Phuoc is an Assistant Member in the Moffitt Cancer Center Department of Ambulatory Hematology/Oncology. Dr. Phuoc received her MD from Baylor College of Medicine in Houston, Texas, and completed an Internal Medicine Residency at Mayo Clinic in Rochester, Minnesota. She completed a Hematology/Oncology Fellowship at the University of South Florida/Moffitt Cancer Center, where she also served as Chief Fellow for the James A. Haley Veterans’ Hospital. Dr. Phuoc's clinical focuses are benign and malignant hematology and breast cancers. She is actively involved in the University of South Florida/Moffitt Cancer Center Hematology/Oncology fellowship education and mentorship, and she is leading development of clinical benign hematology services at Moffitt including Bloodless Medicine and perioperative hematology management programs. She serves as the current Medical Director of Infusion at Moffitt and as the Medical Director of Moffitt Cancer Center at SouthShore.

 

 

Education & Training

Fellowship:

• University of South Florida / Moffitt Cancer Center - Hematology/Oncology

Residency:

• Mayo Clinic School of Graduate Medical Education - Internal Medicine

Medical School:

• Baylor College of Medicine - MD

• Ahmed KA, Kim Y, Armaghani AJ, Arrington JA, Costa RL, Czerniecki BJ, Diaz R, Dowell RA, Extermann M, Forsyth PA, Lee KT, Loftus L, Mills MN, Phuoc VH, Rosa M, Soliman HH, Sam CS, Washington IR, Soyano AE, Han HS. Phase II trial of brain MRI surveillance in stage IV breast cancer. Neurooncol. 2025 Jul.27(6):1550-1558. Pubmedid: 39851040. Pmcid: PMC12309701.
• Patil N, Ravichandran S, Messina J, Kirtane K, Phuoc V, Kubal T, Maharaj S. Cutaneous Reactions to Iron Infusions: A Case Report and Clinical Review. EJHaem. 2025 Aug.6(4):e70094. Pubmedid: 40625824. Pmcid: PMC12232973.
• Jordan A, Jain AG, Koipallil GK, Reddy M, Chakkoli S, Midha S, Phuoc V, Eatrides J, Erhardt C, Patel AK, Rico J, Visweshar N, Mhaskar R, Parikh N, Laber D, Jaglal M. Can we lower the platelet threshold of ≥ 50 × 109/L for performing a lumbar puncture safely in patients with hematological malignancies?. Ann Hematol. 2023 Mar.102(3):663-668. Pubmedid: 36534146.
• Dahmen AS, Phuoc VH, Cohen JB, Sexton WJ, Patel SY. Bloodless surgery in urologic oncology: A review of hematologic, anesthetic, and surgical considerations. Urol Oncol. 2023 Apr.41(4):192-203. Pubmedid: 36470804.
• Phuoc V, Sandoval-Sus J, Chavez JC. Drug therapy for double-hit lymphoma. Drugs Context. 2019 Dec.8. Pubmedid: 31844420. Pmcid: PMC6905641.
• Jain MD, Bachmeier CA, Phuoc VH, Chavez JC. Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma. Ther Clin Risk Manag. 2018 May.14:1007-1017. Pubmedid: 29910620. Pmcid: PMC5987753.